The non-invasive gold standard solution for comprehensive management of liver health
FibroScan® is powered by three unique, patented and validated biomarkers to quickly and easily assess liver health.
Our solutions enable non-invasive diagnosis and monitoring at the point-of-care.
A painless exam performed in less than 4 minutes to provide immediate results at the point-of-care.
Can be performed by any trained operator (physician, nurse, medical assistant).
The non-invasive gold standard solution validated by 4 200+ peer-reviewed publications and 180+ international guidelines.
Standardized examination with exceptional precision and reproducibility that can be utilized in 99% of patients
Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.
LSM by VCTE™ for liver fibrosis assessment
CAP™ for liver steatosis assessment
SSM by VCTE™ for portal hypertension assessment and variceal surveillance*
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Enhance FibroScan® liver disease assessment with biological markers
Optimize clinical workflows with real-time secure data transmission
* SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting
to assess portal hypertension and for variceal surveillance.
Products in the FibroScan® range are class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and are manufactured by Echosens™. FibroScan® devices are intended to provide: Liver stiffness measurements at a shear wave frequency of 50 Hz, liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz and spleen stiffness measurements at a shear wave frequency of 100 Hz (FibroScan® 630 Expert only). These non-invasive devices are intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® devices may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis, and its complications (FibroScan® 630 Expert only). They are used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® devices shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
FibroScan®
